Patents by Inventor Nicole Roth
Nicole Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240156946Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: ApplicationFiled: December 21, 2021Publication date: May 16, 2024Applicants: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
-
Publication number: 20240084212Abstract: A coating composition for producing a coating with an adjustable coefficient of friction.Type: ApplicationFiled: August 30, 2023Publication date: March 14, 2024Applicant: Ewald Dörken AGInventors: Reiner Wark, Nicole Matthée, Angela Kleinkorres, Hanna Smoll, Anastasia von Rhein, Martin Kunka, Marcel Roth, Gerhard Reusmann, Emre Kocak, Ingo Klüppel
-
Publication number: 20240076570Abstract: A coating composition for producing a coating with an adjustable coefficient of friction.Type: ApplicationFiled: August 30, 2023Publication date: March 7, 2024Applicant: Ewald Dörken AGInventors: Reiner Wark, Nicole Matthée, Angela Kleinkorres, Hanna Smoll, Anastasia von Rhein, Martin Kunka, Marcel Roth, Gerhard Reusmann
-
Patent number: 11918643Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: December 21, 2021Date of Patent: March 5, 2024Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
-
Publication number: 20240066114Abstract: The present invention is inter alia directed to compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus membrane protein (M), nucleocapsid protein (N), non-structural protein, and/or accessory protein or an immunogenic fragment or immunogenic variant thereof. The composition may additionally comprise at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus spike protein (S). The nucleic acid sequences of the compositions are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The compositions provided herein are for use in treatment or prophylaxis of an infection with at least one Coronavirus, and may therefore be comprised in a vaccine, preferably a multivalent vaccine.Type: ApplicationFiled: August 30, 2021Publication date: February 29, 2024Applicant: CureVac SEInventors: Susanne RAUCH, Nicole ROTH, Benjamin PETSCH, Wolfgang GROSSE
-
Patent number: 11872280Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: May 31, 2022Date of Patent: January 16, 2024Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
-
Publication number: 20230332011Abstract: Disclosed herein is a solvent-borne, two-pack coating composition. Further disclosed is a method of producing the coating composition, a method for coating and the coatings obtained therein, and the use of compounds (II) and (III) as corrosion inhibitors.Type: ApplicationFiled: August 26, 2021Publication date: October 19, 2023Inventors: Patrick KEIL, Thorsten GELBRICH, Nicole ROTH, Silvia LENTER, Renate WEGNER, Sebastian POEHLKER
-
Publication number: 20220331422Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: ApplicationFiled: May 31, 2022Publication date: October 20, 2022Applicants: CureVac AG, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
-
Publication number: 20220202930Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: ApplicationFiled: December 21, 2021Publication date: June 30, 2022Applicants: CureVac AG, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROSSE, Dominik VAHRENHORST, Susanne RAUCH
-
Publication number: 20220040281Abstract: The present invention is directed to a coding RNA for a Malaria vaccine. The coding RNA comprises at least one heterologous untranslated region (UTR), preferably a 3?-UTR and/or a 5?-UTR, and a coding region encoding at least one antigenic peptide or protein derived from a Malaria parasite, in particular at least one antigenic protein derived from circumsporozoite protein (CSP) of a Malaria parasite (e.g. Plasmodium falciparum). The present invention is also directed to compositions and vaccines comprising said coding RNA in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). Further, the invention concerns a kit, particularly a kit of parts comprising the coding RNA, or the composition, or the vaccine. The invention is also directed to a method of treating or preventing Malaria, and the first and second medical uses of the coding RNA, the composition, the vaccine, and the kit.Type: ApplicationFiled: December 20, 2019Publication date: February 10, 2022Applicant: CureVac AGInventors: Kim Ellen SCHWENDT, Benjamin PETSCH, Nicole ROTH
-
Publication number: 20160251542Abstract: The present invention relates to a use of an aqueous coating composition for applying a topcoat to at least one side of a substrate metal surface coated at least with a primer coat, said aqueous coating composition comprising at least one binder (A) in dispersion or solution in water, at least one crosslinking agent (B), at least one second binder (C) in dispersion or solution in water, and optionally at least one pigment (D), the second binder (C) being a copolymer which is obtainable by copolymerization of ethylenically unsaturated monomers in the presence of at least one polyurethane resin having polymerizable carbon double bonds; to a process for coating a substrate metal surface coated at least with a primer coat, said process comprising at least one step of at least single-sidedly applying the aqueous coating composition as topcoat to the substrate metal surface coated at least with a primer coat; and also to a coated substrate obtainable by this process.Type: ApplicationFiled: September 4, 2014Publication date: September 1, 2016Applicant: BASF Coatings GmbHInventors: Frank JOEGE, Nicole ROTH, Petra TOBOLL
-
Patent number: D464575Type: GrantFiled: January 24, 2002Date of Patent: October 22, 2002Inventors: Jean-Daniel Nicolas Roth, Nicole Roth